Can Targeted Therapy — Cure Cancer?

Remission means no detectable cancer on your scans or tests, but the cancer may still be present at a level too small to see. Cure means the cancer has gone and will not return. For most solid tumours, oncologists are careful about using the word cure even after years in remission, because late recurrence is possible. In a small number of haematological cancers, treatment can produce outcomes durable enough to be considered curative. For most cancers where targeted therapy is used, the goal is a deep, lasting remission and a good quality of life.

The duration varies widely depending on your cancer type, the specific drug, and your individual tumour biology. NCCN and ESMO guidance acknowledges that responses can last months to several years in a proportion of patients, but no timeline can be predicted reliably for any individual. Some people remain on the same drug for years without resistance; others develop it within months. Your oncologist will monitor you with regular scans and blood tests, watching for early signs that the drug is becoming less effective.

Your oncologist will reassess and discuss the next option. Sometimes a different targeted drug works — some cancers have more than one targetable change, and drugs exist for several of them. In other cases, chemotherapy, immunotherapy or a combination becomes the recommended path. Occasionally a repeat biopsy is done, because tumours can change their molecular characteristics over time and a new target may have appeared. Resistance is an expected part of the trajectory for most people on targeted therapy, and planning for it is part of good oncology care.

In a small number of haematological cancers — certain types of leukaemia and lymphoma — targeted therapy has produced responses durable enough that some oncologists use the word curative, though even there the word is used carefully. For most solid tumours, including lung, breast, colon and kidney cancers, targeted therapy aims at long-term control rather than cure. For the cancers most people are thinking about when they ask this question, cure is not the usual outcome, though long disease-free periods are possible in a proportion of patients.

This is determined by molecular testing of your tumour tissue — usually from the biopsy sample you have already had. The laboratory looks for specific mutations, gene fusions or amplifications that correspond to available drugs. Which tests apply depends on your cancer type. If testing has not been offered to you, ask whether it is relevant for your diagnosis. Not every cancer type has actionable targets, but for those that do, molecular testing is part of standard staging and work-up according to NCCN and ESMO guidance.

Yes, and for certain cancer types, combination approaches are the standard of care rather than targeted therapy alone. The combination depends on your cancer type, the specific drugs, and your general fitness. Combinations typically carry the side effects of both treatments. Ask your oncologist specifically which drugs are being considered, why they are being combined, and what each is expected to contribute. That is a reasonable question to put in writing if the conversation moves faster than you can follow.

They are not interchangeable, and the comparison is not straightforward. Targeted therapy is only relevant if your tumour carries the specific target the drug needs. If it does, targeted therapy is often better tolerated than chemotherapy and may produce better responses for your particular cancer. If it does not, targeted therapy will not work regardless of how it compares in principle. The right treatment is the one indicated for your specific molecular profile and cancer type — not the one that sounds more precise or modern.

Yes, it is reasonable to ask whether molecular testing has been done on your tumour and whether targeted therapy is an option for your diagnosis. There are two main reasons it might not have been raised: either it genuinely does not apply to your cancer type or stage, or the testing has not yet been done. Both are answers you deserve to hear clearly. Asking is not challenging your doctor — it is taking part in your own care, and most oncologists welcome it.